22 names are moving together; 95% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| BAX | Baxter International Inc. | Healthcare | -3.5% | Group member |
| STE | STERIS plc (Ireland) | Healthcare | -3.8% | Group member |
| IDXX | IDEXX Laboratories, Inc. | Healthcare | -4.2% | Group member |
| ICUI | ICU Medical, Inc. | Healthcare | -2.5% | Group member |
| MDT | Medtronic plc. | Healthcare | -5.1% | Group member |
| SNN | Smith & Nephew SNATS, Inc. | Healthcare | -4.1% | Group member |
| SYK | Stryker Corporation | Healthcare | -6.1% | Group member |
| ISRG | Intuitive Surgical, Inc. | Healthcare | -6.8% | Group member |
| PODD | Insulet Corporation | Healthcare | -1.8% | Group member |
| ZBH | Zimmer Biomet Holdings, Inc. | Healthcare | -3.2% | Group member |
| BDX | Becton, Dickinson and Company | Healthcare | -2.0% | Most structurally connected |
| MMSI | Merit Medical Systems, Inc. | Healthcare | -3.2% | Group member |
| PHG | Koninklijke Philips N.V. NY Reg | Healthcare | -4.6% | Group member |
| GEHC | GE HealthCare Technologies Inc. | Healthcare | -5.5% | Group member |
| SHC | Sotera Health Company | Healthcare | -2.1% | Group member |
| PEN | Penumbra, Inc. | Healthcare | -0.8% | Group member |
| GMED | Globus Medical, Inc. | Healthcare | -4.9% | Group member |
| MZTI | The Marzetti Company | Consumer Defensive | -6.3% | Group member |
| ABT | Abbott Laboratories | Healthcare | -3.4% | Group member |
| BSX | Boston Scientific Corporation | Healthcare | -4.5% | Group member |
| RMD | ResMed Inc. | Healthcare | -2.6% | Group member |
| ITGR | Integer Holdings Corporation | Healthcare | -3.3% | Group member |
Cohort
22 namesParticipation
95% this sessionObserved history
1 daily buildsFiling coverage
20/22 memberscredit / rates affecting interest expense
“Interest Expense, net Interest expense, net increased by $19 million to $68 million in the first quarter of 2026 primarily due to interest on debt related to the acquisition of Exact Sciences, partially offset by interest income on bond proceeds and prior year debt repayments.”
ABT 10-Q
demand / volume affecting revenue
“34 BioPharma Systems Segment The following summarizes second quarter BioPharma Systems revenues: Three months ended March 31, (Millions of dollars) 2026 2025 Total Change Estimated FX Impact FXN Change BioPharma Systems Revenues $ 590 $ 575 2.5 % 4.3 % (1.8) % The BioPharma Systems segment’s revenues in the second quarter of 2026 reflected a decline primarily driven by lower market demand for vaccines products, partially offset by double-digit growth of prefillable solutions in the biologic drug category, led by sales of GLP-1 delivery products.”
BDX 10-Q
product pipeline / R&D affecting expense
“Research and development expense as a percentage of revenues in the third quarter of 2025 was flat compared with the third quarter of 2024 which primarily reflected costs attributable to the Advanced Patient Monitoring unit, offset by the timing of project spending.”
BDX 10-Q
Medical Devices & Supplies can stay leader-led if ICUI and the next software names fail to join while BDX keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.